Phase 2 clinical trials – Protocol and results
A Phase 2 study conducted in the U.S. in patients with non-small cell lung cancer (NSCLC) has proven the good safety and efficacy of the treatment.
The median survival of patients treated with Tedopi® was 17.3 months, versus 12 months for the control group of HLA-A2 negative patients. With existing second line therapies, the median survival of such patients ranges from five to eight months*.
The results have also shown a one-year survival rate of 59% compared with 33%** for currently available treatments, the one-year survival rate is.
*Source: median survival with existing second line treatment
**Source: survival rate after 1 year with existing second line treatment